{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:31:24Z","timestamp":1787315484530,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background:<\/jats:title>\n Although antipsychotic polypharmacy (APP) is not recommended for the treatment of schizophrenia, it remains a common clinical practice. While APP is generally presumed to be associated with a higher burden of adverse effects, the current evidence remains inconclusive.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n This study compared the adverse effects experienced by patients with schizophrenia (excluding those receiving clozapine) treated with antipsychotic monopharmacy (APM) or APP using both subjective and objective assessments.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This cross-sectional study included 114 patients with schizophrenia (56 receiving APM and 58 receiving APP). Spontaneously reported adverse effects, including their number and type, were recorded. Objective adverse effects were assessed using the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS), Simpson\u2013Angus Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS).<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n No significant differences were observed between the APM and APP groups on the overall subjective or objective measures of adverse effects. However, headache (\n P<\/jats:italic>\n = 0.04), difficulty concentrating (\n P<\/jats:italic>\n = 0.01), constipation (\n P<\/jats:italic>\n = 0.01), restlessness (\n P<\/jats:italic>\n = 0.01), and insomnia (\n P<\/jats:italic>\n = 0.006) were reported significantly more frequently in the APP group. Compared with the APM group, patients receiving APP had a significantly longer duration of illness (\n P<\/jats:italic>\n = 0.004;\n d<\/jats:italic>\n = 0.55), lower treatment adherence (\n P<\/jats:italic>\n = 0.02;\n d<\/jats:italic>\n = 0.25), a higher total chlorpromazine-equivalent dose (\n P<\/jats:italic>\n < 0.001;\n d<\/jats:italic>\n = 1.21), and a higher rate of trihexyphenidyl use (\n P<\/jats:italic>\n = 0.01; \u03c6 = 0.23).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Overall adverse effects were comparable between the APM and APP groups. However, APP was associated with higher antipsychotic and trihexyphenidyl use; more insomnia, restlessness, constipation, and difficulty concentrating; and poorer treatment adherence.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/indianjpsychiatry_8_26","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:18:16Z","timestamp":1787242696000},"page":"692-698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Adverse effect MonoPoly: Antipsychotic monopharmacy vs antipsychotic polypharmacy in the treatment of schizophrenia"],"prefix":"10.4103","volume":"68","author":[{"given":"Shaurya","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Kumar","family":"Praharaj","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"R1-20260821","doi-asserted-by":"crossref","first-page":"e0195687","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLoS One"},{"key":"R2-20260821","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for management of schizophrenia","volume":"59","author":"Grover","year":"2017","journal-title":"Indian J Psychiatry"},{"key":"R3-20260821","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"R4-20260821","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"R5-20260821","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: Benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"key":"R6-20260821","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy: A comprehensive evaluation of relevant correlates of a long-standing clinical practice","volume":"35","author":"Correll","year":"2012","journal-title":"Psychiatr Clin North Am"},{"key":"R7-20260821","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ajp.2019.08.010","article-title":"Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey","volume":"45","author":"Dong","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"R8-20260821","doi-asserted-by":"crossref","first-page":"102022","DOI":"10.1016\/j.ajp.2020.102022","article-title":"Frequency, reasons, and factors associated with antipsychotic polypharmacy in Schizophrenia: A retrospective chart review in a tertiary hospital in India","volume":"51","author":"Shenoy","year":"2020","journal-title":"Asian J Psychiatr"},{"key":"R9-20260821","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ps.52.8.1033","article-title":"Psychopharmacology: Rational and irrational polypharmacy","volume":"52","author":"Kingsbury","year":"2001","journal-title":"Psychiatr Serv"},{"key":"R10-20260821","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1192\/bjp.173.4.325","article-title":"Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study","volume":"173","author":"Waddington","year":"1998","journal-title":"Br J Psychiatry"},{"key":"R11-20260821","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","article-title":"Schizophrenia, neuroleptic medication and mortality","volume":"188","author":"Joukamaa","year":"2006","journal-title":"Br J Psychiatry"},{"key":"R12-20260821","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2020.08.026","article-title":"Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies","volume":"223","author":"Buhagiar","year":"2020","journal-title":"Schizophr Res"},{"key":"R13-20260821","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2013.10.034","article-title":"Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary","volume":"152","author":"Katona","year":"2014","journal-title":"Schizophr Res"},{"key":"R14-20260821","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1440-1819.2012.02376.x","article-title":"Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients","volume":"66","author":"Hashimoto","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"key":"R15-20260821","doi-asserted-by":"crossref","first-page":"2045125320957119","DOI":"10.1177\/2045125320957119","article-title":"Check the effects: Systematic assessment of antipsychotic side-effects in an inpatient cohort","volume":"10","author":"Hynes","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"R16-20260821","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.schres.2007.09.002","article-title":"Antipsychotic polypharmacy does not increase the risk for side effects","volume":"98","author":"Ganesan","year":"2008","journal-title":"Schizophr Res"},{"key":"R17-20260821","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: A cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"R18-20260821","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R19-20260821","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","article-title":"Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia","volume":"58","author":"Sim","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20260821","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/14740338.2016.1165668","article-title":"Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: Results from a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Galling","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R21-20260821","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ajp.2019.02.005","article-title":"Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia","volume":"40","author":"Hatta","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"R22-20260821","first-page":"CD009005","article-title":"Antipsychotic combinations for schizophrenia","volume":"6","author":"Ortiz-Orendain","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-20260821","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/JCP.0000000000000815","article-title":"Antipsychotic polypharmacy and its relation to metabolic syndrome in patients with schizophrenia: An Egyptian study","volume":"38","author":"Aly","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"R24-20260821","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","article-title":"Assessment of adverse effects in clinical studies of antipsychotic medication: Survey of methods used","volume":"197","author":"Pope","year":"2010","journal-title":"Br J Psychiatry"},{"key":"R26-20260821","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":"A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients","volume":"166","author":"Day","year":"1995","journal-title":"Br J Psychiatry"},{"key":"R27-20260821","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R28-20260821","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2377-5-5","article-title":"Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population","volume":"5","author":"Janno","year":"2005","journal-title":"BMC Neurol"},{"key":"R29-20260821","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R30-20260821","article-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976","journal-title":"US Department of Health, Education, and Welfare, Public Health Service"},{"key":"R31-20260821","doi-asserted-by":"crossref","first-page":"80","DOI":"10.12788\/acp.0019","article-title":"Less is more: Deprescribing anticholinergic medications in persons with severe mental illness","volume":"33","author":"Lupu","year":"2021","journal-title":"Ann Clin Psychiatry"},{"key":"R32-20260821","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0447.2005.00589.x","article-title":"Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy","volume":"113","author":"Carnahan","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"R33-20260821","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr Res"},{"key":"R34-20260821","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCP.0000000000000353","article-title":"Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge","volume":"35","author":"Doshi","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"R36-20260821","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","article-title":"The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia","volume":"37","author":"Ang","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"R37-20260821","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","article-title":"Medication adherence in schizophrenia","volume":"2","author":"Acosta","year":"2012","journal-title":"World J Psychiatry"},{"key":"R38-20260821","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/schbul\/sbad126","article-title":"Antipsychotic medication and risk of metabolic disorders in people with schizophrenia: A longitudinal study using the UK Clinical Practice Research Datalink","volume":"50","author":"Eyles","year":"2024","journal-title":"Schizophr Bull"}],"container-title":["Indian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/indianjpsychiatry_8_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:00:41Z","timestamp":1787313641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/indianjpsychiatry_8_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/indianjpsychiatry_8_26","relation":{},"ISSN":["0019-5545","1998-3794"],"issn-type":[{"value":"0019-5545","type":"print"},{"value":"1998-3794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-01-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}